DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: aprepitant

Summary for Generic Name: aprepitant

Tradenames:2
Patents:4
Applicants:2
NDAs:2
Drug Master File Entries: see list11
Suppliers: see list3
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details

Pharmacology for Ingredient: aprepitant

Clinical Trials for: aprepitant

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Status: Recruiting Condition: Chemotherapy Induced Nausea and Vomiting

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Status: Terminated Condition: Chemotherapy-Induced Nausea and Vomiting

Topical Aprepitant in Prurigo Patients
Status: Recruiting Condition: Pruritus

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Status: Completed Condition: Postoperative Nausea and Vomiting

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

Re-examination Study of EMEND (Aprepitant) (MK-0869-184 AM1)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting (CINV)

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sandoz
APREPITANT
aprepitant
CAPSULE;ORAL090999Sep 24, 2012RXNo<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo5,538,982<disabled>TREATMENT OR PREVENTION OF EMESIS
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo5,719,147<disabled>YYTREATMENT OR PREVENTION OF EMESIS
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo6,096,742<disabled>YYTREATMENT OR PREVENTION OF EMESIS
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc